H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

Research and development spending rose 14.3% compared to Q2 2024, reflecting a busy clinical pipeline, while the net loss (GAAP) increased to $10.4 million. These 10 stocks could mint the next wave of ...

Key Points GAAP EPS loss of $9.09 was narrower than the expected $9.24 per share for Q2 2025, a minor outperformance. Research and development expenses (GAAP) rose 29.2% to $2.2 million, reflecting ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20 | ...

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies ...

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license ...

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to inclu ...

Key Takeaways from the Complicated Urinary Tract Infections Pipeline Report ...

Q2 2025 Earnings Call Transcript August 11, 2025 Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported ...